Guí a OncoSur de infecc ione s en pac i ente s con tumor de órgano sól ido 106 > 9. Cheng MP, Abou Chakra CN, Yansouni CP, Cnossen S, Shrier I, Menzies D, et al. Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2017;64(5):635-44. 10. Anastasopoulou A, Ziogas DC, Samarkos M, Kirkwood JM, Gogas H. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer. 2019;7(1):239. 11. Cañas García-Otero E, Praena-Segovia J, Ruiz-Pérez de Pipaón M, Bosh-Guerra X, Sánchez-Agüera M, Álvarez- Martínez D, et al. Clinical approach to imported eosinophilia. Enferm Infecc Microbiol Clin. 2016;34(10):661-84. 12. Salas-Coronas J, Ramírez-Olivencia G, Pérez-Arellano JL, Belhassen-García M, Carranza-Rodríguez C, García-Rodríguez M, et al. Diagnostico y tratamiento de la eosinofilia importada en viajeros e inmigrantes: recomendaciones de la Sociedad Espanola de Medicina Tropical y Salud Internacional (SEMTSI). Rev Esp Quimioter. 2017;30(1):62-78. 13. Kotton CN, Kroger AT, Freedman DO. Chapter 5. Travelers with Additional Considerations. Immunocompromised Travelers. Centers for Disease Control and Prevention. CDC Yellow Book 2020: Health Information for International Travel. New York: Oxford University Press; 2017. 14. Dhanireddy S, Yuan Zhou Y, McClellan S. Chapter 15: The Immunocompromised Traveler. En: The Travel and Tropical Medicine 2017 manual, 5th ed. Sanford CAPottinger WS, JongWC (editors). London: Elsevier Inc.; 2017.
RkJQdWJsaXNoZXIy OTI4NTYw